Prophylactic intravenous immune globulin and polymixin B decrease the incidence of septic episodes and hospital length of stay in severely burned children.
After burn shock resuscitation, serum gamma globulin levels decrease well below normal before slowly recovering over the course of 1 to 2 months. During this period, patients are vulnerable to further insult as a result of this immunocompromise. We hypothesized that intravenous immune globulin and subtherapeutic polymixin B (IVIG-B) could decrease the incidence and/or severity of sepsis after major thermal injury. A retrospective chart review from 1997 through 2003 at two hospitals compared patients who received IVIG-B (Hospital A) with those who did not (Hospital B). Patients with burns 40% or greater TBSA were included, whereas patients with nonsurvivable injuries were excluded from data analysis. A total of 152 patients were included in the study. One hundred two patients received IVIG-B, and 50 did not. Total burn size was 63.4% TBSA at Hospital A and 63.1% TBSA at Hospital B, with full-thickness burns of 54.4 and 61.7% TBSA, respectively (P < .05). Patients treated at Hospital A had a 51.9% incidence of inhalation injury compared with 28% of the patients at Hospital B (P < .05). There was an average of 1.2 and 1.9 septic episodes for patients treated at Hospital A and Hospital B, respectively (P < .05). Length of hospital stay was 77.1 days at Hospital A compared with 103.8 days at Hospital B (P < .05). Mortality was 17.6% and 18% at Hospitals A and B, respectively, and was not significantly different. Our data suggest that prophylactic IVIG-B is associated with a reduction in the incidence of septic episodes and decreased hospital length of stay following major thermal injury.
Lyons
Jefferson M
JM
Department of Surgery, University of Cincinnati College of Medicine, Cincinnati, Ohio 45229-3095, USA.
Davis
Christopher
C
Rieman
Mary T
MT
Kopcha
Robert
R
Phan
Ho
H
Greenhalgh
David
D
Palmieri
Tina
T
Kagan
Richard
R
D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D019072:Antibiotic Prophylaxis; D002056:Burns / Q000150:complications / Q000188:drug therapy* / Q000401:mortality; D002648:Child; D005260:Female; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use*; D007155:Immunologic Factors / Q000627:therapeutic use*; D007902:Length of Stay / Q000706:statistics & numerical data*; D008297:Male; D011112:Polymyxin B / Q000627:therapeutic use*; D012189:Retrospective Studies; D012772:Shock, Septic / Q000453:epidemiology / Q000209:etiology / Q000517:prevention & control*; D015208:Smoke Inhalation Injury / Q000453:epidemiology; D015599:Trauma Severity Indices
D000900:Anti-Bacterial Agents; D016756:Immunoglobulins, Intravenous; D007155:Immunologic Factors; D011112:Polymyxin B